York Pharma Plc is a USA based company, which is developing pharmaceutical products for skin care, announces progress in the development of SabarepÂ, York’s patented treatment for atopic eczema and related diseases of the skin.
Â Tests carried out by York show that human subjects identify the optimal composition of this multi-component product. The company has also discovered additional novelty during the course of these studies and has filed a new patent to enhance further its strong intellectual property position in the area of skin protease inhibition.
The functional mechanistic studies of Phase II design (vehicle and placebo controlled) generatedÂ data from 114 human subjects, involving 149 tests on these subjects, with 760 skin sites tested.
Â Also earlier this month, York held a meeting with the UK medicines regulator (MHRA) to review the results generated to date with SabarepÂ and to agree the requirements for the remainder of its development programme prior to the regulatory submission for a Marketing Authorisation.